"Either tyrosine kinase inhibitors or monoclonal antibodies
Action:
Tyrosine kinase inhibitors bind to the tyrosine kinase domain in the HER2 and stops activation of the signaling pathway.
Monoclonal antibodies bind to the extracellular component of the HER2
prevent the actual substrates from binding to the receptors and stop the receptor activation"